What is the share price of SMS Lifesciences India Ltd (SMSLIFE) today?
The share price of SMSLIFE as on 18th March 2025 is ₹1066.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on SMS Lifesciences India Ltd (SMSLIFE) share?
The past returns of SMS Lifesciences India Ltd (SMSLIFE) share are- Past 1 week: -6.88%
- Past 1 month: -17.24%
- Past 3 months: -9.65%
- Past 6 months: -29.82%
- Past 1 year: 74.20%
- Past 3 years: 44.52%
- Past 5 years: 437.62%
What are the peers or stocks similar to SMS Lifesciences India Ltd (SMSLIFE)?
The peers or stocks similar to SMS Lifesciences India Ltd (SMSLIFE) include:What is the dividend yield % of SMS Lifesciences India Ltd (SMSLIFE) share?
The current dividend yield of SMS Lifesciences India Ltd (SMSLIFE) is 0.14.What is the market cap of SMS Lifesciences India Ltd (SMSLIFE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SMS Lifesciences India Ltd (SMSLIFE) is ₹316.16 Cr as of 18th March 2025.What is the 52 week high and low of SMS Lifesciences India Ltd (SMSLIFE) share?
The 52-week high of SMS Lifesciences India Ltd (SMSLIFE) is ₹1749.65 and the 52-week low is ₹609.85.What is the PE and PB ratio of SMS Lifesciences India Ltd (SMSLIFE) stock?
The P/E (price-to-earnings) ratio of SMS Lifesciences India Ltd (SMSLIFE) is 34.74. The P/B (price-to-book) ratio is 1.63.Which sector does SMS Lifesciences India Ltd (SMSLIFE) belong to?
SMS Lifesciences India Ltd (SMSLIFE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy SMS Lifesciences India Ltd (SMSLIFE) shares?
You can directly buy SMS Lifesciences India Ltd (SMSLIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
SMS Lifesciences India Ltd
SMSLIFESMS Lifesciences India Ltd
SMSLIFE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹316 cr, stock is ranked 2,026
High RiskStock is 4.02x as volatile as Nifty
1,066.101.95% (+20.35)
1,066.101.95% (+20.35)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 13.72 | 1.63 | 0.14% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.31 | 6.04 | 0.55% |
Forecast & Ratings
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
SMS Lifesciences India is engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of organic and inorganic chemicals,pharmaceuticals
Peers
Compare with peersSUNPHARMA
PE Ratio
42.70
1Y Return
11.24%
Buy Reco %
88.24
CIPLA
PE Ratio
29.25
1Y Return
1.36%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
62.65
1Y Return
22.03%
Buy Reco %
68.00
DRREDDY
PE Ratio
17.19
1Y Return
8.24%
Buy Reco %
45.16
LUPIN
PE Ratio
47.50
1Y Return
26.03%
Buy Reco %
63.64
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Annual Normal View
Income Statement
Annual Normal View
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 380.36 | 263.06 | 267.37 | 364.50 | 320.98 | 309.79 | 350.50 | |||||||
Raw Materials | 268.79 | 147.04 | 135.17 | 204.47 | 171.33 | 150.19 | 296.64 | |||||||
| Power & Fuel Cost | 25.93 | 20.48 | 21.56 | 30.02 | 29.28 | 30.46 | ||||||||
| Employee Cost | 23.11 | 26.56 | 30.66 | 39.90 | 43.43 | 49.27 | ||||||||
| Selling & Administrative Expenses | 11.98 | 9.28 | 12.28 | 13.77 | 12.52 | 14.20 | ||||||||
| Operating & Other expenses | 13.28 | 32.02 | 35.68 | 27.37 | 30.18 | 30.62 | ||||||||
EBITDA | 37.27 | 27.68 | 32.02 | 48.97 | 34.24 | 35.05 | 53.86 | |||||||
| Depreciation/Amortization | 6.38 | 7.86 | 7.86 | 10.01 | 10.79 | 14.94 | 14.98 | |||||||
| PBIT | 30.89 | 19.82 | 24.16 | 38.96 | 23.45 | 20.11 | 38.88 | |||||||
| Interest & Other Items | 5.51 | 5.15 | 4.60 | 6.23 | 6.87 | 10.26 | 9.52 | |||||||
| PBT | 25.38 | 14.67 | 19.56 | 32.73 | 16.58 | 9.85 | 29.36 | |||||||
| Taxes & Other Items | 7.54 | 4.49 | 6.02 | 7.41 | 5.13 | 0.75 | 6.31 | |||||||
| Net Income | 17.84 | 10.18 | 13.54 | 25.32 | 11.45 | 9.10 | 23.05 | |||||||
| EPS | 59.01 | 33.67 | 44.79 | 83.75 | 37.87 | 30.10 | 76.24 | |||||||
| DPS | 1.50 | 0.00 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | |||||||
| Payout ratio | 0.03 | 0.00 | 0.03 | 0.02 | 0.04 | 0.05 | 0.02 |
Company Updates
FY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFPeers & Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| SMS Lifesciences India Ltd | 34.74 | 1.63 | 0.14% |
| Sun Pharmaceutical Industries Ltd | 42.70 | 6.09 | 0.79% |
| Cipla Ltd | 29.25 | 4.50 | 0.87% |
| Torrent Pharmaceuticals Ltd | 62.65 | 15.14 | 0.91% |
Price Comparison
Compare SMSLIFE with any stock or ETFCompare SMSLIFE with any stock or ETF
SMSLIFE
Shareholdings
Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2024
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 22, 2023
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 22, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 22, 2022
Cash Dividend
Ex DateEx DateSep 20, 2021
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 20, 2021
Cash Dividend
Ex DateEx DateSep 19, 2019
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 19, 2019
News & Opinions
Articles & Videos
Spotlight
SMS Lifesciences India spurts as Q3 PAT jumps 18% YoY to Rs 5 cr
Revenue from operations was at Rs 84.60 crore in the third quarter of FY25, marking a growth of 17.41% compared with Rs 72.05 crore in Q3 FY24. In Q3 FY25, the profit before tax (PBT) spiked 81.36% year on year (YoY) to Rs 6.91 crore. Total expenses added 12.96% YoY to Rs 77.74 crore in the quarter ended 31 December 2024. Cost of materials consumed was at Rs 39.43 crore (up 0.61% YoY), and employee benefits expense was at Rs 14.60 crore (up 9.69% YoY) during the period under review. On a nine-month basis, the company reported consolidated net profit of Rs 15.24 crore in 9M FY25, compared with net loss of Rs 0.14 crore posted in 9M FY24. Revenue from operations jumped 18.35% YoY to Rs 255.61 crore in 9M FY25. Meanwhile, the board has approved the reappointment of Veeravenkata Satyanarayana Murthy Talluri as managing director (MD) of the company for a further period of 3 consecutive year's w.e.f. 1 June 2025. SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents, and generally dealing with all types of organic & inorganic chemicals, pharmaceuticals, active pharmaceutical ingredients (API), and intermediates. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
SMS Lifesciences India consolidated net profit rises 27.21% in the December 2024 quarter
Net profit of SMS Lifesciences India rose 27.21% to Rs 5.47 crore in the quarter ended December 2024 as against Rs 4.30 crore during the previous quarter ended December 2023. Sales rose 17.42% to Rs 84.60 crore in the quarter ended December 2024 as against Rs 72.05 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales84.6072.05 17 OPM %15.0712.89 - PBDT10.677.54 42 PBT6.923.81 82 NP5.474.30 27 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
SMS LifeSciences India to announce Quarterly Result
SMS LifeSciences India will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
SMS Lifesciences India consolidated net profit rises 586.76% in the September 2024 quarter
Net profit of SMS Lifesciences India rose 586.76% to Rs 4.67 crore in the quarter ended September 2024 as against Rs 0.68 crore during the previous quarter ended September 2023. Sales rose 13.28% to Rs 78.46 crore in the quarter ended September 2024 as against Rs 69.26 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales78.4669.26 13 OPM %10.9111.45 - PBDT8.475.39 57 PBT4.701.66 183 NP4.670.68 587 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
SMS LifeSciences India to conduct board meeting
SMS LifeSciences India will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
SMS LifeSciences India AGM scheduled
SMS LifeSciences India announced that the 18th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
SMS Lifesciences India reports consolidated net profit of Rs 7.00 crore in the June 2024 quarter
Net profit of SMS Lifesciences India reported to Rs 7.00 crore in the quarter ended June 2024 as against net loss of Rs 1.80 crore during the previous quarter ended June 2023. Sales rose 23.98% to Rs 92.55 crore in the quarter ended June 2024 as against Rs 74.65 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales92.5574.65 24 OPM %17.593.39 - PBDT14.320.97 1376 PBT10.64-2.73 LP NP7.00-1.80 LP Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
SMS LifeSciences India schedules board meeting
SMS LifeSciences India will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
SMS Lifesciences India consolidated net profit rises 59.80% in the March 2022 quarter
2 years agoBusiness Standard
SMS Lifesciences India divests 10% stake of wholly-owned subsidiary, Mahi Drugs
2 years agoBusiness Standard
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -4.02%, vs industry avg of 9.04%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.17% to 0.08%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -12.6%, vs industry avg of 15.28%